Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

ClinicalTrials.gov IDNCT07321886

PhasePHASE3

Enrollment1980

SponsorEli Lilly and Company

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Obesity, Overweight

About this study

Interventions

Drug: Eloralintide — Administered SC
Drug: Placebo — Administered SC

Primary outcomes

Percent Change from Baseline in Body Weight (Baseline, Week 64)

Eligibility information

Inclusion Criteria: * Have Body Mass Index (BMI) at screening of the following: * 30 kilogram per square meter (kg/m2) OR * 27 kg/m2 with at least one of the following weight-related health conditions at screening: * high blood pressure * dyslipidemia * obstructive sleep apnea, or * heart disease * Have a stable body weight (\<5% body weight change) for 90 days prior to screening. * Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes or type 2 diabetes * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Study locations

MFA Clinical Research, Tuscaloosa, Alabama 35405 United States
Headlands Research - Scottsdale, Scottsdale, Arizona 85260 United States
Neighborhood Healthcare Institute of Health, Escondido, California 92025 United States
Ark Clinical Research - Fountain Valley, Fountain Valley, California 92708 United States
Desert Oasis Healthcare Medical Group, Palm Springs, California 92262 United States
Peninsula Research Associates, Rolling Hills Estates, California 90274 United States
Care Access - Sacramento, Sacramento, California 95831 United States
Southern California Clinical Research, Santa Ana, California 92701 United States
University Clinical Investigators, Inc., Tustin, California 92780 United States
Chase Medical Research, LLC, Waterbury, Connecticut 06708 United States

Showing 10 of 158 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-29.